Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3670-3681

  McPhee, Fiona ^a   Friborg, Jacques ^a   Levine, Steven ^a   Chen, Chaoqun ^a   Falk, Paul ^a   Yu, Fei ^a   Hernandez, Dennis ^a   Lee, Min S ^a   Chaniewski, Susan ^a   Sheaffer, Amy K ^a   Pasquinelli, Claudio ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ASUNAPREVIR;

ADULT; ARTICLE; DRUG SENSITIVITY; ENZYME ASSAY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; REPLICON; TRANSIENT TRANSFECTION; TREATMENT RESPONSE; VIRUS REPLICATION; VIRUS RESISTANCE; WILD TYPE;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS C; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROTEASE INHIBITORS; SULFONAMIDES; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 84862560600     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00308-12     Document Type: Article

References (48)

1. Argentini C, Genovese D, Dettori S, Rapicetta M. 2009. HCV genetic variability: from quasispecies evolution to genotype classification. Future Microbiol. 4:359-373.
2. Bacon BR, et al. 2011. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364:1207-1217.
3. Blight KJ, Kolykhalov AA, Rice CM. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974.
4. Bronowicki J, et al. 2011. BMS-650032, an NS3 inhibitor (protease), in combination with peginterferon alfa-2a and ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis C infection. J. Hepatol. 54(Suppl 1):S472.
5. Chayama K, et al. 2012. Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b infected null responders. Hepatology 55:742-748.
6. Drexler D, et al. 2006. Development of an on-line automated sample clean-up method and liquid chromatography-tandem mass spectrometry analysis: application in an in vitro proteolytic assay. Anal. Bioanal. Chem. 384:1145-1154.
7. Food and Drug Administration. 2011. Boceprevir prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/202258lbl.pdf.
8. Food and Drug Administration. 2011. Telaprevir prescribing information. Accessed 1 April 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 201917lbl.pdf.
9. Fridell RA, et al. 2011. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J. Virol. 85:7312-7320.
10. Fridell RA, Qiu D, Wang C, Valera L, Gao M. 2010. Resistance analysis of the hepatitisCvirus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother. 54(9):3641-3650.
11. Fried MW, et al. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
12. Gao M, et al. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96-100.
13. Gaudieri S, et al. 2009. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 49:1069-1082.
14. Ghany MG, Strader DB, Thomas DL, Seeff LB. 2009. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335-1374.
15. Jacobson IM, et al. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364:2405-2416.
16. Kadow JF, et al. 2012. Discovery of BMS-791325, an allosteric NS5B replicase inhibitor for the treatment of hepatitis C, abstr. 23. In Sci. Abstr. 243rd ACS Natl. Meet. Exposition.
17. Kim JL, et al. 1996. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87:343-355.
18. Krieger N, Lohmann V, Bartenschlager R. 2001. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75:4614-4624.
19. Kuiken C, Yusim K, Boykin L, Richardson R. 2005. The Los Alamos hepatitis C sequence database. Bioinformatics 21:379-384.
20. Lagace L, et al. 2012. In vitro resistance profile of the HCV NS3 protease inhibitor BI 201335. Antimicrob. Agents Chemother. 56(1):569-572.
21. Lallos L, et al. 2009. Preclinical profiles of IDX136 and IDX316, two novel macrocyclic HCV protease inhibitors, poster 344. In 44th Annu. Meet. Eur. Assoc. Study Liver (EASL), Copenhagen, Denmark, 22 to 26 April 2009.
22. Lemm JA, et al. 2005. Replication-competent chimeric hepatitis C virus subgenomic replicons. Intervirology 48:183-191.
23. Lenz O, et al. 2010. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob. Agents Chemother. 54:1878-1887.
24. Liverton NJ, et al. 2010. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob. Agents Chemother. 54:305-311.
25. Lohmann V, Korner F, Dobierzewska A, Bartenschlager R. 2001. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J. Virol. 75:1437-1449.
26. Lohmann V, et al. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
27. Lok AS, et al. 2012. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366(3):216-224.
28. McHutchison JG, et al. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361:580-593.
29. McPhee F, et al. 2009. Genotypic and phenotypic analysis of samples from HCV-infected subjects treated with BMS-650032 in a single ascending dose study. Hepatology 50(4):1048A.
30. McPhee F, et al. 2011. No early virologic breakthrough observed with the HCV NS3 protease inhibitor BMS-650032 in multiple dose monotherapy studies and phase 2A combination studies with PEGIFN/RBV. J. Hepatol. 54(Suppl 1):A1223.
31. McPhee F, et al. 2009. The discovery and early development of the HCV NS3 protease inhibitor BMS-605339. Global Antiviral J. 5(Suppl 1):51.
32. McPhee F, et al. 2010. Identification and preclinical profile of the novel HCV NS3 protease inhibitor BMS-650032. J. Hepatol. 52(Suppl 1):S296.
33. Nettles RE, et al. 2011. Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 54(6):1956-1965.
34. Pasquinelli C, et al. 2012. Single and multiple ascending dose studies of the NS3 protease inhibitor, asunaprevir, in subjects with or without chronic hepatitis C. Antimicrob. Agents Chemother. 56:1838-1844.
35. Poordad F, et al. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364:1195-1206.
36. Qiu P, et al. 2009. Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res. 37:e74. doi:10.1093/nar/gkp251.
37. Raney KD, Sharma SD, Moustafa IM, Cameron CE. 2010. Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target. J. Biol. Chem. 285:22725-22731.
38. Reesink HW, et al. 2006. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131:997-1002.
39. Romano KP, Ali A, Royer WE, Schiffer CA. 2010. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc. Natl. Acad. Sci. U. S. A. 107:20986-20991.
40. Sarrazin C, et al. 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767-1777.
41. Scola P, et al. 2010. Discovery of BMS-650032, an NS3 protease inhibitor for the treatment of hepatitis C, abstr. MEDI-38. In Sci. Abstr. 239th ACS Natl. Meet. Exposition.
42. Sheaffer AK, et al. 2004. Characterisation of HCV replicons resistant to inhibitors of NS3 protease activity, abstr. 290. In Proc. 7th Int. Symp. Positive Strand RNA Viruses.
43. Sheaffer AK, et al. 2011. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences fromHCVclinical isolates. Antivir. Ther. 16:705-718.
44. Susser S, et al. 2009. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology. 50:1709-1718.
45. Tong X, et al. 2008. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res. 77:177-185.
46. Verbinnen T, et al. 2010. Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. J. Virol. 84:11124-11133.
47. World Health Organization. 2011. Hepatitis C key facts. http://www.who.int/mediacentre/factsheets/fs164/en/.
48. Yanagi M, Purcell RH, Emerson SU, Bukh J. 1997. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc. Nat. Acad. Sci. U. S. A. 94:8738-8743.